Chlamydia pneumoniae activates nuclear factor κB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation

Journal of Surgical Research

Volumn 90, Issue 1, 2000, Pages 76-81

  Miller, Stephanie A ^a   Selzman, Craig H ^a   Shames, Brian D ^a   Barton, Hazel A ^a   Johnson, Sylene M ^a   Harken, Alden H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Activator protein 1; Atherosclerosis; Azithromycin; Chlamydia pneumoniae; Nuclear factor KB; Proliferation; Vascular smooth muscle

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROLIDE; TRANSCRIPTION FACTOR AP 1;

AORTA; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; DNA BINDING; DRUG EFFECT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0034192620     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2000.5847     Document Type: Conference Paper

References (30)

1. Saikku P., Leinonen M., Mattila K., Ekman M. R., Nieminen M. S., Makela P. H., Huttunen J. K., Valtonen V. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 2:1988;983.
2. Jackson L. A., Campbell L. A., Schmidt R. A., Kuo C. C., Cappuccio A. L., Lee M. J., Grayston J. T. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis. Am. J. Pathol. 150:1997;1785.
3. Juvonen J., Juvonen T., Laurila A., Alakarppa H., Lounatmaa K., Surcel H. M., Leinonen M., Kairaluoma M. I., Saikku P. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J. Vasc. Surg. 25:1997;499.
4. Kuo C. C., Coulson A. S., Campbell L. A., Cappuccio A. L., Lawrence R. D., Wang S. P., Grayston J. T. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J. Vasc. Surg. 26:1997;29.
5. Grayston J. T., Kuo C. C., Coulson A. S., Campbell L. A., Lawrence R. D., Lee M. J., Strandness E. D., Wang S. P. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery [see comments]. Circulation. 92:1995;3397.
6. Godzik K. L., O'Brien E. R., Wang S. K., Kuo C. C. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J. Clin. Microbiol. 33:1995;2411.
7. Gaydos C. A., Summersgill J. T., Sahney N. N., Ramirez J. A., Quinn T. C. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect. Immun. 64:1996;1614.
8. Yamashita K., Ouchi K., Shirai M., Gondo T., Nakazawa T., Ito H. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke. 29:1998;773.
9. Ross R. Atherosclerosis: An inflammatory disease. N. Engl. J. Med. 340:1999;115.
10. Selzman C. H., Shames B. D., Reznikov L. L., Miller S. A., Meng X., Barton H. A., Werman A., Harken A. H., Dinarello C. A., Banerjee A. Liposomal delivery of purified inhibitory-κBα inhibits tumor necrosis factor-α-induced human vascular smooth muscle proliferation. Circ. Res. 84:1999;867.
11. Suggs W. D., Olson S. C., Mandani D., Patel S., Veith F. J. Antisense oligonucleotides to c-fos and c-jun inhibit intimal thickening in a rat vein graft model. Surgery. 126:1999;443.
12. Selzman C. H., McIntyre R. C., Shames B. D., Whitehill T. A., Banerjee A., Harken A. H. Interleukin-10 inhibits human vascular smooth muscle proliferation. J. Mol. Cell. Cardiol. 30:1998;889.
13. Roblin P. M., Dumornay W., Hammerschlag M. R. Use of Hep-2 cells for improved isolation and passage of Chlamydia pneumoniae. J. Clin. Microbiol. 30:1992;1968.
14. Epstein S. E., Zhou Y. F., Zhu J. Infection and atherosclerosis: Emerging mechanistic paradigms. Circulation. 100:1999;e20.
15. Grayston J. T. Does Chlamydia pneumoniae cause atherosclerosis? Arch. Surg. 134:1999;930.
16. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur. Heart. J. 14:1993;57.
17. Grayston J. T., Kuo C. C., Campbell L. A., Benditt E. P. Chlamydia pneumoniae, strain TWAR and atherosclerosis. Eur. Heart J. 14:1993;66.
18. Laitinen K., Laurila A., Pyhala L., Leinonen M., Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect. Immun. 65:1997;4832.
19. Coombes B. K., Mahony J. B. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect. Immun. 67:1999;2909.
20. Heinemann M., Susa M., Simnacher U., Marre R., Essig A. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect. Immun. 64:1996;4872.
21. Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., Page M., Kaltschmidt C., Baeuerle P. A., Neumeier D. Activated transcription factor nuclear factor-κB is present in the atherosclerotic lesion. J. Clin. Invest. 97:1996;1715.
22. Hernandez-Presa M. A., Gomez-Guerrero C., Egido J. In situ nonradioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry. Kidney Int. 55:1999;209.
23. Engel J. N. Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. Antimicrob. Agents Chemother. 36:1992;2304.
24. Nakajima T., Kitajima I., Shin H., Takasaki I., Shigeta K., Abeyama K., Yamashita Y., Tokioka T., Soejima Y., Maruyama I. Involvement of NF-κB activation in thrombin-induced human vascular smooth muscle cell proliferation. Biochem. Biophys. Res. Commun. 204:1994;950.
25. Selzman C. H., Shames B. D., McIntyre R. C. Jr., Banerjee A., Harken A. H. The NFκB inhibitory peptide, IκBα, prevents human vascular smooth muscle proliferation. Ann. Thorac. Surg. 67:1999;1227.
26. Cosenza S. C., Yumet G., Soprano D. R., Soprano K. J. Induction of c-fos and c-jun mRNA at the M/G1 border is required for cell cycle progression. J. Cell Biochem. 55:1994;503.
27. Pai S. R., Bird R. C. c-fos expression is required during all phases of the cell cycle during exponential cell proliferation. Anticancer Res. 14:1994;985.
28. Muhlestein J. B., Anderson J. L., Hammond E. H., Zhao L., Trehan S., Schwobe E. P., Carlquist J. F. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:1998;633.
29. Gupta S., Leatham E. W., Carrington D., Mendall M. A., Kaski J. C., Camm A. J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404.
30. Anderson, J. L, Muhlestein, J. B, Carlquist, J, Allen, A, Trehan, S, Nielson, C, Hall, S, Brady, J, Egger, M, Horne, B, and, Lim, T. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study [see comments], Circulation, 99, 1540, 1999.